[1] Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol, 2021,18(3):151-166.
[2] Wang FD, Zhou J, Chen EQ. Molecular mechanisms and potential new therapeutic drugs for liver fibrosis. Front Pharmacol, 2022,13:787748.
[3] Prestigiacomo V, Weston A, Suter-Dick L. Rat multicellular 3D liver microtissues to explore TGF-β1 induced effects. J Pharmacol Toxicol Methods, 2020,101:106650.
[4] Collins SD, Yuen G, Tu T, et al. In vitro models of the liver: disease modeling, drug discovery and clinical applications. Tirnitz-Parker JEE. Hepatocellular Carcinoma [Internet]. Brisbane (AU): Codon Publications, 2019.
[5] Farzaneh Z, Khojastehpour F, Keivan M, et al. Co-culture of liver parenchymal cells with non-parenchymal cells under 2D and 3D culture systems; a review paper. Curr Stem Cell Res Ther, 2023,18(7):904-916..
[6] Prestigiacomo V, Weston A, Messner S, et al. Pro-fibrotic compounds induce stellate cell activation, ECM-remodelling and Nrf2 activation in a human 3D-multicellular model of liver fibrosis. PLoS One, 2017 ,12(6):e0179995.
[7] Lauschke VM, Shafagh RZ, Hendriks DFG, et al. 3D primary hepatocyte culture systems for analyses of liver diseases, drug metabolism, and toxicity: emerging culture paradigms and applications. Biotechnol J, 2019, 14(7):e1800347.
[8] Lee SA, No da Y, Kang E, et al. Spheroid-based three-dimensional liver-on-a-chip to investigate hepatocyte-hepatic stellate cell interactions and flow effects. Lab Chip, 2013, 13(18):3529-3537.
[9] Thomas RJ, Bhandari R, Barrett DA, et al. The effect of three-dimensional co-culture of hepatocytes and hepatic stellate cells on key hepatocyte functions in vitro. Cells Tissues Organs, 2005, 181(2):67-79.
[10] Bell CC, Hendriks DF, Moro SM, et al. Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. Sci Rep, 2016, 6:25187.
[11] Baze A, Parmentier C, Hendriks DFG, et al. Three-dimensional spheroid primary human hepatocytes in monoculture and coculture with nonparenchymal cells. Tissue Eng Part C Methods, 2018, 24(9):534-545.
[12] Mannaerts I, Eysackers N, Anne van Os E, et al. The fibrotic response of primary liver spheroids recapitulates in vivo hepatic stellate cell activation. Biomaterials, 2020, 261:120335.
[13] Lee HJ, Mun SJ, Jung CR, et al. In vitro modeling of liver fibrosis with 3D co-culture system using a novel human hepatic stellate cell line. Biotechnol Bioeng, 2023,120(5):1241-1253.
[14] Ma L, Wu Y, Li Y, et al. Current advances on 3D-bioprinted liver tissue models. Adv Healthc Mater, 2020, 9(24):e2001517.
[15] Cui X, Li J, Hartanto Y, et al. Advances in extrusion 3D bioprinting: a focus on multicomponent hydrogel-based bioinks. Adv Healthc Mater, 2020, 9(15):e1901648.
[16] Yan Y, Wang X, Pan Y, et al. Fabrication of viable tissue-engineered constructs with 3D cell-assembly technique. Biomaterials, 2005, 26(29):5864-5871.
[17] Nguyen DG, Funk J, Robbins JB, et al. Bioprinted 3D primary liver tissues allow assessment of organ-level response to clinical drug induced toxicity in vitro. PLoS One, 2016, 11(7):e0158674.
[18] Norona LM, Nguyen DG, Gerber DA, et al. Editor's highlight: modeling compound-induced fibrogenesis in vitro using three-dimensional bioprinted human liver tissues. Toxicol Sci, 2016, 154(2):354-367.
[19] Cuvellier M, Ezan F, Oliveira H, et al. 3D culture of HepaRG cells in GelMa and its application to bioprinting of a multicellular hepatic model. Biomaterials, 2021, 269:120611.
[20] Wang T, Lü S, Hao Y, et al. Influence of microflow on hepatic sinusoid blood flow and red blood cell deformation. Biophys J, 2021, 120(21):4859-4873.
[21] Orbach SM, Ford AJ, Saverot SE, et al. Multi-cellular transitional organotypic models to investigate liver fibrosis. Acta Biomater, 2018, 82:79-92.
[22] Du Y, Li N, Yang H, et al. Mimicking liver sinusoidal structures and functions using a 3D-configured microfluidic chip. Lab Chip, 2017, 17(5):782-794.
[23] Li W, Li P, Li N, et al. Matrix stiffness and shear stresses modulate hepatocyte functions in a fibrotic liver sinusoidal model. Am J Physiol Gastrointest Liver Physiol, 2021, 320(3):G272-G282.
[24] Kabirian F, Mozafari M. Decellularized ECM-derived bioinks: prospects for the future. Methods, 2020, 171:108-118.
[25] Dai Q, Jiang W, Huang F, et al. Recent advances in liver engineering with decellularized scaffold. Front Bioeng Biotechnol, 2022, 10:831477.
[26] Hoshiba T. Decellularized extracellular matrix for cancer research. Materials (Basel), 2019, 12(8):1311.
[27] Zhang X, Chen X, Hong H, et al. Decellularized extracellular matrix scaffolds: Recent trends and emerging strategies in tissue engineering. Bioact Mater, 2021, 10:15-31.
[28] Caralt M, Uzarski JS, Iacob S, et al. Optimization and critical evaluation of decellularization strategies to develop renal extracellular matrix scaffolds as biological templates for organ engineering and transplantation. Am J Transplant, 2015, 15(1):64-75.
[29] Thanapirom K, Caon E, Papatheodoridi M, et al. Optimization and validation of a novel three-dimensional co-culture system in decellularized human liver scaffold for the study of liver fibrosis and cancer. Cancers (Basel), 2021, 13(19):4936.
[30] Palma E, Doornebal EJ, Chokshi S. Precision-cut liver slices: a versatile tool to advance liver research. Hepatol Int, 2019, 13(1):51-57.
[31] Mazza G, Al-Akkad W, Rombouts K. Engineering in vitro models of hepatofibrogenesis. Adv Drug Deliv Rev, 2017, 121:147-157.
[32] Dewyse L, Reynaert H, van Grunsven LA. Best practices and progress in precision-cut liver slice cultures. Int J Mol Sci, 2021, 22(13):7137.
[33] Dewyse L, De Smet V, Verhulst S, et al. Improved precision-cut liver slice cultures for testing drug-induced liver fibrosis. Front Med (Lausanne), 2022, 9:862185.
[34] Paish HL, Reed LH, Brown H, et al. A bioreactor technology for modeling fibrosis in human and rodent precision-cut liver slices. Hepatology, 2019, 70(4):1377-1391.
[35] Sun L, Hui L. Progress in human liver organoids. J Mol Cell Biol, 2020, 12(8):607-617.
[36] Artegiani B, Clevers H. Use and application of 3D-organoid technology. Hum Mol Genet, 2018, 27(R2):R99-R107.
[37] Harrison SP, Baumgarten SF, Verma R, et al. Liver organoids: recent developments, limitations and potential. Front Med (Lausanne), 2021, 8:574047.
[38] Arjmand B, Rabbani Z, Soveyzi F, et al. Advancement of organoid technology in regenerative medicine. Regen Eng Transl Med, 2023, 9(1):83-96.
[39] Leite SB, Roosens T, El Taghdouini A, et al. Novel human hepatic organoid model enables testing of drug-induced liver fibrosis in vitro. Biomaterials, 2016, 78:1-10.
[40] Brovold M, Keller D, Soker S. Differential fibrotic phenotypes of hepatic stellate cells within 3D liver organoids. Biotechnol Bioeng, 2020, 117(8):2516-2526.
[41] Ouchi R, Togo S, Kimura M, et al. Modeling steatohepatitis in humans with pluripotent stem cell-derived organoids. Cell Metab, 2019, 30(2):374-384.e6. |
